On minimizing risk and harm in the use of psychedelics (2025)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use (2025)

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals (2024)

Learning how to make use of dissociative therapies (2024)

At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data (2024)

Predictors of treatment outcome for parent-led, transdiagnostic cognitive behavioral therapy for youth with emotional problems related to the COVID-19 pandemic (2024)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective, longitudinal survey (2023)

Double-blind comparison of the two hallucinogens dextromethorphan and psilocybin: Experience-dependent and enduring psychological effects in healthy volunteers (2023)

Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine (2023)

Toward synergies of ketamine and psychotherapy (2022)

Mapping consent practices for outpatient psychiatric use of ketamine (2022)

The conundrum of therapeutic intoxication (2022)

Brief, parent-led, transdiagnostic cognitive-behavioral teletherapy for youth with emotional problems related to the COVID-19 pandemic (2022)

A qualitative inquiry of parents’ observations of their children’s mental health needs during the COVID-19 pandemic (2021)

Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality (2021)

The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review (2020)

Recovery from impaired working memory performance during chronic Δ-9-tetrahydrocannabinol administration to adolescent rhesus monkeys (2020)

Deep transcranial magnetic stimulation for obsessive compulsive disorder (2020)

Use of guanfacine for cannabis use disorder and related symptomatology (2019)

Guanfacine attenuates adverse effects of dronabinol (THC) on working memory in adolescent-onset heavy cannabis users: A pilot study (2017)

Persistent and long-term neuropsychiatric implications of cannabis use in adolescents (2017)

Paradoxical increase in synthetic cannabinoid emergency-related presentations after city wide ban: Lessons from Houston, Texas (2016)

“Just one bad high”:Considering synthetic cannabinoid outcome expectancies in adolescents (2016)

Borderline personality disorder and a spectrum of trauma (2015)